- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02954705
MICRO-RNAs OF NEUTROPHILS IN RENAL ANTINEUTROPHIL CYTOPLASMIS ANTIBODY (ANCA) -ASSOCIATED VASCULITIS (MINERVA)
October 21, 2020 updated by: Nantes University Hospital
MICRO-RNAs OF NEUTROPHILS IN RENAL ANCA-ASSOCIATED VASCULITIS
Activation of neutrophils by ANCA ("Anti-Neutrophil Cytoplasm Antibodies") and subsequent microvascular endothelial cell damage is the main feature of ANCA-associated vasculitis (AAV), a severe autoimmune disease that often targets the kidney.
There is no specific treatment for AAV to date and 25% of patients with renal damage evolve towards end-stage renal disease, requiring dialysis and kidney transplantation.
In addition, there is no reliable biological marker of the disease activity available, which makes the diagnostic, follow-up and treatment of patients difficult.
Therefore, the identification of new therapeutic targets and non-invasive biomarkers constitutes a major clinical challenge to improve AAV patients care and to ameliorate their renal outcome.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
63
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Nantes, France, 44093
- Nantes University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
This will be done in total in 50 patients with ANCA-associated vasculitis (AAV) and 20 control patients.
Among the 50 patients with AAV, 30 patients will be newly diagnosed and 20 already followed for AAV
Description
Inclusion Criteria for patients:
- Adult patients aged over 18 years
- Patients with Granulomatosis with polyangiitis or microscopic polyangiitis meeting the criteria of Chapel Hill.
- corticosteroid treatment <20 mg / day.
- Informed consent: oral for participation in research and writing for biological collection.
Inclusion Criteria for controls patients:
- healthy-topics matched for age, recruited from the Etablissement français du sang or in the Department of Internal Medicine of Nantes University Hospital
Non Inclusion Criteria:
- ANCA-associated vasculitis with Eosinophilic granulomatosis with polyangiitis (AAV-EGPA).
- Infectious or progressive tumor pathology.
- Pregnancy, lactation
- Treatment with cyclophosphamide in the 6 months prior to inclusion.
- Terminal chronic renal failure, presence of organ allograft.
- Thrust Patients receiving corticosteroids> 20 mg / d in the previous 4 weeks.
- Inability to give informed about information (subject in emergencies, understanding of the subject of difficulty, ...)
- Minor subject, under judicial protection, guardianship
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Group AAV
Patients recruited from the Nantes University Hospital.
50 milliliter of blood and 10mL of urine are collected from these patients during levies in clinical visit.
|
This is a non interventional study because all levies are performed during visit planned for the care of patients.
|
Group control
People recruited from the "Etablissement français du sang" (French blood establishment ). 10 milliliter of blood are collected from these donors |
This is a non interventional study because all levies are performed during visit planned for the care of patients.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Expression profile of miRNAs in patients with AAV in circulating neutrophils, plasma and urine.
Time Frame: 6 month after maintenance treatment
|
6 month after maintenance treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Fadi Fakhouri, Pr, Nantes University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 28, 2017
Primary Completion (Actual)
December 31, 2019
Study Completion (Actual)
September 30, 2020
Study Registration Dates
First Submitted
November 2, 2016
First Submitted That Met QC Criteria
November 2, 2016
First Posted (Estimate)
November 3, 2016
Study Record Updates
Last Update Posted (Actual)
October 22, 2020
Last Update Submitted That Met QC Criteria
October 21, 2020
Last Verified
October 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RC15_0454
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ANCA-associated Vasculitis
-
University Hospital, Strasbourg, FranceRecruiting
-
Xiangya Hospital of Central South UniversityThe Third Xiangya Hospital of Central South University; Hunan Provincial People... and other collaboratorsRecruiting
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)TerminatedANCA-Associated VasculitisUnited Kingdom
-
Chinese SLE Treatment And Research GroupThe First Affiliated Hospital of Anhui Medical University; Shanghai Zhongshan... and other collaboratorsRecruitingANCA Associated Vasculitis | Maintenance TherapyChina
-
University Hospital, BrestNot yet recruitingOccupational Diseases | ANCA Associated Vasculitis | Environmental ExposureFrance
-
University Hospital Birmingham NHS Foundation TrustMerck Sharp & Dohme LLCRecruitingANCA Associated VasculitisUnited Kingdom
-
Shanghai Zhongshan HospitalCompletedDrug Use | ANCA Associated Vasculitis | JAK-STAT Pathway DeregulationChina
-
Second Affiliated Hospital, School of Medicine,...RecruitingANCA Associated VasculitisChina
-
University of North Carolina, Chapel HillNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)SuspendedANCA Associated VasculitisUnited States
-
Chinese SLE Treatment And Research GroupPeking Union Medical College HospitalRecruitingANCA Associated VasculitisChina
Clinical Trials on Non interventional study
-
Universitätsklinikum Hamburg-EppendorfSandozUnknownPsoriasisDenmark, Spain, Germany, Poland
-
University Hospital, RouenRecruitingDyspepsia | Irritable Bowel Syndrome | Functional Constipation | Faecal IncontinenceFrance
-
Mayo ClinicRecruitingOropharyngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage III Oropharyngeal (p16-Negative)... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute...RecruitingMalignant Solid Neoplasm | Hematopoietic and Lymphatic System NeoplasmUnited States
-
Mayo ClinicRecruitingStage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | Stage IIIA Bladder Cancer AJCC v8 | Stage II Bladder Cancer AJCC v8United States
-
Mayo ClinicRecruitingClear Cell Renal Cell Carcinoma | Urothelial Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Kidney Oncocytoma | Clear Cell Papillary Renal TumorUnited States
-
Mayo ClinicRecruitingProstate CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI); National Institute for Biomedical Imaging...RecruitingProstate NeoplasmUnited States
-
University of WashingtonNational Cancer Institute (NCI)RecruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal CarcinomaUnited States
-
Mayo ClinicRecruitingBreast CarcinomaUnited States